Cefepime for Injection recalled due to sterility assurance failure
Astral SteriTech's Cefepime for Injection (1 gram per vial, 550,160 vials nationwide) is being recalled due to lack of assurance of sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving injectable medication with a sterility assurance failure. No illnesses or injuries have been reported in the source text, making this a theoretical contamination hazard despite the potential for serious infection if the product were administered. This fits the rubric criterion for Score 3: risk-of-harm products where injury has not yet been reported.
Plain-English summary
Astral SteriTech Private Ltd., manufacturing for Xellia Pharmaceuticals USA LLC, is recalling Cefepime for Injection, USP 1 gram per vial (NDC 70594-089-02) due to lack of assurance of sterility.
The recall affects 550,160 vials distributed nationwide within the United States. All lots within the product's expiry date are included in this recall.
The issue is that these injectable vials cannot be assured to maintain proper sterility. Healthcare providers and patients who may have access to affected product should consult with their pharmacist or healthcare provider before use.
The FDA has designated this as a Class II recall. Affected individuals can contact the FDA or the manufacturer for additional information and guidance.
The recalled product
- Product
- Cefepime for Injection, USP 1 gram per vial, Manufactured for: Xellia Pharmaceuticals USA, LLC, Buffalo Grove, IL 60089, NDC 70594-089-02
- Manufacturer
- Astral SteriTech Private Ltd.
- Category
- Drug — Injectable / Antibiotic
- Hazard
- sterility-assurance
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27